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Cleidocranial dysplasia (CCD) is an autosomal dominant skeletal dysplasia caused by heterozygosity of mutations
in human RUNX2. The disorder is characterized by delayed closure of the fontanel and hypoplastic clavicles that
result from defective intramembranous ossification. However, additional features, such as short stature and cone
epiphyses, also suggest an underlying defect in endochondral ossification. Here, we report observations of growth-
plate abnormalities in a patient with a novel RUNX2 gene mutation, a single C insertion (1228insC), which is
predicted to lead to a premature termination codon and thus to haploinsufficiency of RUNX2 and the CCD
phenotype. Histological analysis of the rib and long-bone cartilages showed a markedly diminished zone of hy-
pertrophy. Quantitative real-time reverse transcription–polymerase chain reaction analysis of limb cartilage RNA
showed a 5–10-fold decrease in the hypertrophic chondrocyte molecular markers VEGF, MMP13, and COL10A1.
Together, these data show that humans with CCD have altered endochondral ossification due to altered RUNX2
regulation of hypertrophic chondrocyte–specific genes during chondrocyte maturation.
Runx2 is a well-characterized critical transcriptional reg-
ulator of osteoblast differentiation (Ducy et al. 1997;
Komori et al. 1997; Otto et al. 1997). Heterozygosity
for mutations in RUNX2 causes cleidocranial dysplasia
(CCD [MIM 119600]), an autosomal dominant skeletal
dysplasia characterized by hypoplastic clavicles, short
stature, and tooth anomalies (Lee et al. 1997; Mundlos
et al. 1997; Lee and Zhou 2004). Runx2-deficient mice
(/) have no bone formation, whereas the heterozy-
gote mice (/) display abnormalities similar to those
seen in individuals with CCD (Shapiro 1999). Runx2
heterozygote mice have fewer osteoblasts and bone-spe-
cific proteins, and the enzyme activity of alkaline phos-
phatase is low (Shapiro 1999). Furthermore, molecular
and mouse genetic studies demonstrate that the abnor-
mal bone formation is mainly due to Runx2 transcrip-
tional regulation of its target genes during osteoblast
differentiation. In osteoblasts, transcription of the bone-
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specific osteocalcin gene is principally regulated by the
Runx2 transcription factor and is stimulated in response
to vitamin via the vitamin receptor complex (Si-D D3 3
erra et al. 2003). Beyond the skeleton, studies suggest
that Runx2 regulates the expression of molecules in mes-
enchyme that act reciprocally on the dental epithelium
to control its growth and differentiation, and this partly
explains the dental abnormalities found in patients with
CCD and in Runx2 heterozygote mice (D’Souza et al.
1999; Zou et al. 2003).
The CCD characteristics of delayed closure of the
fontanel and hypoplastic clavicles reflect defective intra-
membranous ossification. However, the significantly hy-
poplastic or absent clavicles point to an effect on both
intramembranous and endochondral ossification, be-
cause the clavicle ossifies embryologically by both routes
(Huang et al. 1997). Recent reports that emphasize short
stature as a prominent feature in CCD provide sup-
porting evidence for RUNX2 effects on endochondral
ossification (Cooper et al. 2001; Morava et al. 2002).
In addition, mouse genetics studies have shown altered
chondrocyte maturation or defective chondrocyte hy-
pertrophy in some long bones of Runx2 null mice (Inada
et al. 1999; Enomoto et al. 2000). Growth-plate com-
pression and decreased expression of Col10a1 (a hy-
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Figure 2 Hematoxylin and eosin staining and immunohisto-
chemical analysis of the CCD and control femur sections. The legend
is available in its entirety in the online edition of The American Journal
of Human Genetics.
Figure 1 Molecular and histological analyses of a fetus with CCD. A, Sequencing of exon 9 of RUNX2 alleles shows the mutant allele
with a C insertion in the PST domain (1228insC) and the wild-type allele (WT). The relative position of this mutation is shown in the schematic
representation of the RUNX2 structure. Q/Ap polyglutamine/polyalanine domain; RUNTp DNA-binding runt domain. B, Von Kossa staining
and immunohistochemical analysis of the CCD rib cartilage. For an age-matched control fetal rib section (Ctrl), Von Kossa histological analysis
shows a normal hypertrophic zone (top left panel), and type X collagen immunostaining exhibits normal extracellular staining of type X collagen
in the hypertrophic zone (arrowheads in bottom left panel). Separation of primary spongiosa is an artifact of tissue preparation. For the rib
section from the fetus with CCD, Von Kossa staining shows a much shortened hypertrophic zone (top right panel), and type X collagen
immunostaining shows flattened hypertrophic chondrocytes, with both reduced and asymmetric type X collagen expression within the compressed
hypertrophic zone (arrowheads in bottom right panel). HZ p hypertrophic zone of growth plate.
pertrophic chondrocyte–specific molecular marker) have
also been reported in Runx2 heterozygote mice (Zheng
et al. 2003). However, the molecular and histologi-
cal correlates in human development have only been
extrapolated.
In this study, we report the molecular, immunohis-
tochemical, and histological characterization of growth-
plate abnormalities in a 20-wk fetus with CCD and a
novel RUNX2 gene mutation. Prenatal diagnosis of a
de novo case of CCD was made by ultrasonography at
19 wk. On the basis of ultrasound long-bone measure-
ments, the 20-wk fetus was smaller than normal, with
limb lengths consistent with 19-wk gestation, and absent
clavicles and a hypomineralized calvarium were noted.
Relevant tissues, including the entire distal femoral car-
tilage, were harvested at autopsy. RUNX2 exons were
PCR amplified from genomic DNA by use of intron-
specific primers, as described elsewhere (Lee et al. 1997).
Direct sequencing of this PCR-amplified RUNX2 gene
revealed a single C insertion (1228insC) resulting in a
frameshift mutation in codon 410 (fig. 1A). The muta-
tion was confirmed by cloning and sequencing of each
allele. This mutation is predicted to lead to a premature
termination codon at amino acid 489 in the proline,
serine, and threonine–rich (PST) transactivation domain
and to alteration of the identity of the last 112 amino
acids in the peptide (fig. 1A). On the basis of previous
work, this mutation is predicted to cause haploinsuffi-
ciency and to produce the CCD phenotype (Lee et al.
1997; Mundlos et al. 1997; Zhou et al. 1999). Inter-
estingly, one nearby mutation (1205insC), which leads
to a frameshift in codon 402, was reported to cause a
severe CCD phenotype, with osteoporosis, recurrent
bone fractures, and scoliosis (Quack et al. 1999). An-
other adjacent R391X premature termination mutation
was previously reported to be associated with classic
CCD; in an in vitro transfection study, this mutated pro-
tein showed only 20% transactivation of the reporter
activity, compared with wild-type Runx2 (Zhou et al.
1999).
To study the putative skeletal deficiency in this fetus
with CCD, we performed histologic analysis of rib and
other long-bone cartilage from the fetus and an age-
matched control. The rib, tibia, and femur from the fetus
with CCD and the control were formalin-fixed and em-
bedded in paraffin. Von Kossa staining was performed
on 5-mm sagittal sections (Lowe and Bancroft 1996). The
rib growth-plate sections of the fetus with CCD showed
a markedly diminished zone of hypertrophy and dis-
organized growth-plate chondrocytes, compared with
those of the age-matched control (fig. 1B, upper panel).
Similar findings were also found for the ulna and tibia
(data not shown). Because of the significant shortened
zone of hypertrophy, we performed immunohistochem-
ical analysis with both rib and limb sections, using an
antibody specific to type X collagen (from Dr. Robin
Pool, Montreal), a molecular marker of chondrocyte hy-
pertrophy during endochondral ossification. The result
showed altered type X collagen expression and locali-
zation. In the control growth plate, type X collagen
staining was seen primarily in the pericellular matrix. In
contrast, in the CCD growth plate, the type X collagen
staining was poorly visible in the extracellular matrix
and was more localized to intracellular space (fig. 1B,
lower panel, and figs. 2 and 3). These data together
suggest an important function for RUNX2 in human
endochondral ossification, linking haploinsufficiency
of RUNX2, decreased chondrocyte hypertrophy, and
altered type X collagen expression and distribution in
CCD.
Runx2 has been shown to be an important regulator
of chondrocyte maturation, by in vitro cell culture and
in vivo mouse genetics studies (Inada et al. 1999; Kim
et al. 1999; Enomoto et al. 2000; Takeda et al. 2001;
Ueta et al. 2001). In Runx2-deficient mice (/), chon-
drocyte differentiation was reported to be severely dis-
turbed (Inada et al. 1999), and lack of hypertrophic
chondrocytes with delayed onset of hypertrophy has also
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Figure 3 Von Kossa staining and immunohistochemical analysis
of the CCD and control rib cartilage sections. The legend is available
in its entirety in the online edition of The American Journal of Human
Genetics.
Table 1
Sequences of Primers Used for PCR Amplification
The table is available in its entirety in the online
edition of The American Journal of Human Genetics.
been observed (Kim et al. 1999). Although type X col-
lagen was barely detectable in Runx2 null mice, osteo-
pontin, bone sialoprotein, and collagenase 3 (MMP-13)
were also not expressed in hypertrophic chondrocytes,
indicating that they are regulated by Runx2 in terminal
hypertrophic chondrocytes (Inada et al. 1999). In recent
studies, this has been shown to be the result of direct
Runx2 regulation of their respective promoters (Sato et
al. 1998; Jimenez et al. 1999; Zheng et al. 2003; Wang
et al. 2004). Vascular endothelial growth factor (VEGF),
a critical regulator of angiogenesis during development,
is another direct transcriptional target of Runx2. Runx2
is required for a tissue-specific genetic program that
regulates VEGF during endochondral bone formation
(Zelzer et al. 2001). More recently, mouse genetics stud-
ies have pointed out the possible cooperative function
of Runt gene family members—Runx1, Runx2, and
Runx3—in skeletal development. Runx1 mediates early
events of endochondral and intramembranous bone for-
mation, Runx3 cooperates with Runx2 in promoting
chondrocyte maturation, and Runx2 is a potent inducer
of late stages of chondrocyte and osteoblast differenti-
ation (Yoshida et al. 2004; Smith et al. 2005).
To further characterize the molecular mechanisms and
signaling pathways that are involved in the pathogenesis
of CCD in humans, we performed quantitative real-time
RT-PCR analysis of growth-plate RNA, to determine the
status of the RUNX2 transcriptional network in carti-
lage. We performed assays for the relative expression
levels of known RUNX2 targets VEGF, MMP13, and
COL10A1, as well as for the transcription factor genes
RUNX1, RUNX2, RUNX3, and SOX9. Total RNAs
from CCD and age-matched control cartilages (from bi-
lateral distal femurs) were extracted as described else-
where (Zheng et al. 2003). cDNA synthesis from the
total RNA, real-time PCR amplification of target genes,
and analysis of the real-time PCR results for fold in-
duction of gene expression were performed in accor-
dance with the manufacturer’s protocol and as in pre-
viously reported procedures with modifications (Livak
and Schmittgen 2001; Pfaffl 2001; Zheng et al. 2003).
The sequences of the primers used for PCR amplification
of RUNX1, RUNX2, RUNX3, COL10A1, MMP13,
SOX9, VEGF, and GAPDH are listed in table 1. The
GAPDH gene was used as an internal control for the
quantity and quality of the cDNAs.
Our results showed that the level of RUNX2 mRNA
was ∼50% downregulated in the CCD cartilage, as com-
pared with the control cartilage, suggesting that hap-
loinsufficiency of RUNX2 results from the frameshift
mutation described above (figs. 1A and 4A). This mu-
tation, which sits in the last exon of RUNX2, is predicted
to lead to a premature termination codon (PTC). How-
ever, nonsense-mediated mRNA decay (NMD) cannot
be excluded for this mutant allele (Maquat 2004). It has
been reported that a PTC mutation leading to complete
NMD causes collagen X haploinsufficiency in Schmid
metaphyseal chondrodysplasia cartilage (Bateman et al.
2003). However, since this mutation resides in the last
exon, a potential translated mRNA that escapes NMD
is possible, although the production of a truncated pro-
tein has never been demonstrated for this condition.
Interestingly, sequencing of 10 independent RT-PCR
cDNAs showed that 3 of 10 contain the mutant allele,
which suggests the possibility that the transcript escapes
NMD. We also examined the hypertrophic chondrocyte–
related molecular markers COL10A1, MMP-13, and
VEGF, and they all showed a 5–10-fold decrease in
mRNA levels (fig. 4B, 4C, and 4D). These genes are
highly expressed in terminally differentiated chondro-
cytes. Because of the significantly shortened zone of hy-
pertrophy, we dissected the whole growth-plate carti-
lages to examine the expression level of the specific genes
mentioned above, with normalization to the house-keep-
ing gene GAPDH. Although the reduced expression of
target genes might be partially due to the reduced num-
ber of hypertrophic chondrocytes, these data generated
in human tissue correlate well with the in vitro and in
vivo data for mice showing the direct regulation of the
respective target promoters by Runx2 during skeletal
development (Jimenez et al. 1999; Zelzer et al. 2001;
D’Alonzo et al. 2002; Zheng et al. 2003). The obser-
vation of a shortened zone of hypertrophy was pre-
viously reported for Runx2 heterozygote mice and
also correlates well with human data (Zheng et al.
2003). No change in mRNA levels was observed for
RUNX1 (fig. 4E). Interestingly, we also examined the
RUNX3 mRNA level by real-time RT-PCR analysis,
and it showed a 4-fold upregulation in CCD cartilage,
compared with control cartilage (fig. 4F). This raises
the question of whether RUNX3 expression may be up-
regulated in compensation for loss of RUNX2. Recent
Figure 4 Real-time RT-PCR analysis of genes expressed in limb cartilage. Amplification was performed on a LightCycler (Fast Start DNA
Master SYBR Green I [Roche Diagnostics]). Analysis of the results (i.e., the relative gene expression level) was achieved by normalization to
GAPDH and by comparison with the age-matched control for fold induction. A, The mRNA level of RUNX2 is decreased by 50% in the fetus
with CCD, compared with the control. B, C, and D, The hypertrophic chondrocyte–related molecular markers COL10A1, MMP-13, and VEGF
showed 10-, 7.6-, and 8-fold decreases in mRNA levels, respectively. E, No change in mRNA level was observed for RUNX1. F, RUNX3
showed 4-fold up-regulation in fetus with CCD, compared with the age-matched control. Each real-time RT-PCR experiment was performed
in triplicate, and one representative set of results is presented here, with SDs shown by error bars. Ctrl p age-matched control.
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mouse genetics studies suggest that both Runx2 and
Runx3 are essential for chondrocyte maturation and that
the delayed chondrocyte maturation in Runx2 hetero-
zygotes on a Runx3 null background demonstrated that
Runx3 is required for endochondral ossification when
the Runx2 gene dosage is halved (Yoshida et al. 2004;
Komori 2005). No mRNA level change was observed
for SOX9, a transcription factor required for chondro-
genesis and a regulator of the type II collagen gene (Le-
febvre et al. 1998). This supports the selective defect
present in prehypertrophic and hypertrophic chondro-
cytes and not in the proliferating and resting chondro-
cytes of the growth plate in this fetus with CCD.
CCD is caused by haploinsufficiency of RUNX2, and
no significant phenotypic differences have been observed
between patients with deletions or frameshifts and pa-
tients with missense mutations of RUNX2 (Quack et al.
1999). There is a correlation between phenotypic short
stature and tooth anomalies in some patients with CCD
(Yoshida et al. 2003). Unlike many skeletal dysplasias
that primarily affect cartilage, CCD affects both cartilage
and bone (Mundlos 1999; Hermanns and Lee 2001; Lee
and Zhou 2004). Since RUNX2 is required for both
osteoblast differentiation and chondrocyte maturation,
it links chondrocyte and osteoblast differentiation dur-
ing endochondral bone formation (Mundlos 1999; de
Crombrugghe et al. 2001). Many other transcription fac-
tors, such as the Sox family members, and signaling
molecules, including Indian hedgehog, parathyroid hor-
mone, and related peptide (PTH/PTHrP) and fibroblast
growth factors, also link chondrocyte and osteoblast dif-
ferentiation pathways during endochondral bone for-
mation (Lanske et al. 1996; Vortkamp et al. 1996; Schi-
pani et al. 1997; St-Jacques et al. 1999; Chung et al.
2001; de Crombrugghe et al. 2001). Not surprisingly,
some of these pathways have been shown to impinge on
Runx2 activity. Our studies demonstrate altered chon-
drocyte hypertrophy in human CCD, with decreased ex-
pression of hypertrophic chondrocyte–related markers
that have been shown to be transcriptional targets of
Runx2 in mouse genetics studies (Jimenez et al. 1999;
Zelzer et al. 2001; Wong et al. 2003; Zheng et al. 2003;
Varghese et al. 2005). On the basis of these data and
observations in mice, we can conclude that abnormal
endochondral ossification in CCD results from altered
RUNX2 regulation of chondrocyte hypertrophy and is
associated with downregulation of important RUNX2
transcriptional targets, including COL10A1, VEGF, and
MMP13.
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